Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

281 sites for NCT04824092

ALK Fusion, +4 more biomarkers

ALK-Positive Large B-Cell Lymphoma, +7 more conditions

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

A Phase 3 Trial of Epcoritamab in R/R DLBCL

97 sites for NCT04628494

BCL2 Fusion, +3 more biomarkers

Diffuse Large B-Cell Lymphoma, +5 more conditions

epcoritamab

immunotherapy

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

57 sites for NCT04799275

BCL2 Fusion, +2 more biomarkers

Diffuse Large B-Cell Lymphoma, +15 more conditions

azacitidine, +1 more drug

chemotherapy

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

71 sites for NCT03570892

ALK Alternative Transcription Site, +7 more biomarkers

ALK-Positive Large B-Cell Lymphoma, +13 more conditions

chemotherapy, +1 more drug

cellular therapy, +2 more types

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

16 sites for NCT05020015

BCL2 Fusion, +2 more biomarkers

Diffuse Large B-Cell Lymphoma, +11 more conditions

allogeneic iC9/CD19-CAR-CD28-zeta-2A-IL15-transduced cord blood-derived natural killer cells, +1 more drug

cellular therapy, +2 more types

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

58 sites for NCT04833114

BCL2 Fusion, +2 more biomarkers

Diffuse Large B-Cell Lymphoma, +8 more conditions

polatuzumab vedotin, +1 more drug

chemotherapy, +1 more type

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

1 site for NCT04980222

BCL2 Fusion, +3 more biomarkers

Diffuse Large B-Cell Lymphoma, +3 more conditions

glofitamab, +3 more drugs

chemotherapy, +2 more types

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

30 sites for NCT04384484

BCL2 Fusion, +2 more biomarkers

Diffuse Large B-Cell Lymphoma, +2 more conditions

loncastuximab tesirine, +1 more drug

chemotherapy, +1 more type

Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

3 sites for NCT04546620

BCL2 Fusion, +3 more biomarkers

ALK-Positive Large B-Cell Lymphoma, +8 more conditions

acalabrutinib, +4 more drugs

chemotherapy, +3 more types

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

45 sites for NCT04442022

BCL2 Fusion, +2 more biomarkers

Diffuse Large B-Cell Lymphoma, +3 more conditions

cisplatin, +5 more drugs

chemotherapy, +3 more types

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

9 sites for NCT04920617

BCL2 Fusion, +2 more biomarkers

Diffuse Large B-Cell Lymphoma, +4 more conditions

cyclophosphamide, +2 more drugs

chemotherapy, +1 more type

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

1 site for NCT04594798

BCL2 Fusion, +2 more biomarkers

Composite Lymphoma, +6 more conditions

cyclophosphamide, +4 more drugs

chemotherapy, +3 more types